WuXi Biologics

WuXi Biologics (2269.HK) is a premier global Contract Research, Development, and Manufacturing Organization (CRDMO) dedicated to accelerating and transforming the discovery, development, and manufacturing of innovative biologics. Operating with the foundational vision that "every biologic can be made," the company provides end-to-end solutions that empower pharmaceutical and biotech partners worldwide to bring life-saving therapeutics from concept to commercialization faster and more cost-effectively. With a massive global footprint spanning China, the United States, Ireland, Germany, and Singapore, WuXi Biologics leverages a workforce of over 13,000 scientists and bioprocessing experts to actively support nearly 1,000 integrated client projects globally.

The company's core technological infrastructure represents the absolute cutting edge of the biopharmaceutical supply chain. WuXi Biologics handles a vast array of complex modalities, including monoclonal antibodies, bispecifics, antibody-drug conjugates (ADCs), and advanced microbial fermentation. In recent years, the company has aggressively evolved into a "digital-native" powerhouse, pioneering intelligent lab and factory systems powered by computational modeling, predictive analytics, and digital twin platforms like PatroLab™. These innovations significantly de-risk the scale-up process, slash development timelines, and ensure consistent, high-yield manufacturing across its 15 highly regulated, GMP-certified global facilities.

Guided by CEO Dr. Chris Chen, WuXi Biologics is currently navigating a complex geopolitical landscape with exceptional financial and operational resilience. Despite recent industry headwinds surrounding the U.S. BIOSECURE Act—which was signed into law in late 2025 but notably omitted WuXi Biologics from its initial statutory list of restricted entities—the company continues to secure record-breaking contracts and expand its global capacity. Moving through the first half of 2026, WuXi Biologics reported a highly successful 2025 fiscal year marked by a 16.7% revenue jump, and recently celebrated the structural completion of a massive new microbial commercial manufacturing site in Chengdu. Bolstered by an unwavering commitment to green technology and recently named an Industry ESG Leader by Morningstar Sustainalytics for the sixth consecutive year, WuXi Biologics remains an indispensable manufacturing backbone for the global life sciences ecosystem.